Infections, Nosocomial, Infections, Respiratory Tract
Conditions
Keywords
A. baumannii., Biofilm, ZnO NPs, hospital aquired infections
Brief summary
A. baumannii is known as the most frequently isolated organism in intensive care units (ICUs), causing a variety of nosocomial infections, including pneumonia, urinary tract infections (UTIs), bacteremia as well as skin and soft tissue infections. These infections are usually associated with high mortality rates ranging between 26% among hospitalized patients and 43% among ICU patients.
Detailed description
Acinetobacter baumannii (A. baumannii) is Gram- negative, aerobic, glucose non-fermentative, non-motile coccobacillus, ubiquitous in nature, and persistent in healthcare settings. It is regarded as a significant opportunistic human pathogen. This bacterium become a growing problem in hospitals as a predominant multidrug-resistant (MDR) bacterium. Horizontal acquisition of resistance genes is the main factor involved in the emergence of MDR . There are many mechanisms to confer resistance to different classes of antibiotics in A. baumannii, one of them is multidrug efflux pumps. These efflux pumps are important source of MDR, which export antibiotics from the cell, increasing their antibiotic resistance. AdeABC is one of the most important efflux systems, belonging to the RND family in Acinetobacter, which plays an important role in the resistance to a broad group of antibiotics; its genes are chromosomal and encode three genes, i.e., AdeB, AdeA, and AdeC, forming an operon in the vicinity. In addition, the expression of AdeABC is done by a two-component system, which includes a response regulator (AdeR) and a sensor kinase (AdeS) . The ability of Acinetobacter spp. to form biofilm that enables bacterial survival in hospital settings, especially in ICUs, is the most significant contributing factor to their virulence, and this trait is also responsible for their notable antibiotic resistance. Several biofilm-related genes influence antimicrobial susceptibility, suggesting an association between the biofilm-forming ability of Acinetobacter spp. and their antibiotic resistance patterns (MDR/XDR) Zinc oxide nanoparticles (ZnO NPs) are one of the most important nanoparticles of metal oxides; it is a unique and inorganic materials that can be used in several biological applications (anti-bacterial, anti-inflammatory). ZnO NPs exhibit distinctive properties other than other nanoparticles such as higher solubility, better biofilm penetration and effective drug delivery . ZnO NPs have been reported to have antimicrobial properties such as disrupting the cell membrane of pathogens, accumulating in the cell and producing toxic H2O2 (hydrogen peroxide)
Interventions
Samples will be cultured on MacConkey agar. Morphological identifications of growth isolates by Gram staining, colony features and conventional biochemical tests. All isolates will be identified to species level using automated bacterial identification systems.
Strains confirmed as A. baumannii will be examined for their different antibiotic susceptibility by modified Kirby Bauer\'s disc diffusion method on Mueller Hinton Agar.
The biofilm formation activity of A. baumannii isolates will be tested using the microtitre plate technique
Detection of the effect of ZnO NPs on the biofilm producer MDR A. baumannii strains using the same method
\- Evaluation the effect of ZnO NPs on the expression of some efflux pump genes, and biofilm related genes in MDR A. baumannii isolates using Real time PCR technology.
Sponsors
Study design
Eligibility
Inclusion criteria
* All patients suffering from infections that can be caused by A. baumannii.
Exclusion criteria
* All patients suffering from infections that aren\'t caused by A. baumannii.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| A. baumannii antibiotic susceptibility profile | October 2024 to December 2025 | A. baumannii antibiotic susceptibility profile will be done using modified kirbybeur method |
| Isolation and identification of A. baumannii from different clinical samples | October 2024 to December 2025 | Isolation and identification of A. baumannii from different clinical samples using MacConKey medium, oxidase test. TSI, And automated identification ViteK system |
| A. baumannii strains which produce biofilm | October 2024 to December 2025 | Detection of A. baumannii strains which produce biofilm using tissue culture plates and Gram stain |
| Ability of ZnO NPs to inhibit the phenomenon of biofilm formation by MDR A. baumannii strains | October 2024 to December 2025 | Assessment of ability of ZnO NPs to inhibit the phenomenon of biofilm formation by MDR A. baumannii strains using ZnO NPs to be applied by different concentrations on tissue culture plates and measure the degree of Biofilm formation using ELISA |
| The effect of ZnO NPs on the expression of some efflux pump genes and biofilm related genes in MDR A. baumannii strains | October 2024 to December 2025 | Evaluation the effect of ZnO NPs on the expression of some efflux pump genes and biofilm related genes in MDR A. baumannii strains using real time PCR(Polymerase Chain reaction) |
Countries
Egypt